Angion Biomedica First Quarter 2023 Earnings: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)

Angion Biomedica (NASDAQ:ANGN) First Quarter 2023 Results

Key Financial Results

• Net loss: US$4.54m (loss narrowed by 68% from 1Q 2022).
• US$0.15 loss per share (improved from US$0.47 loss in 1Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Angion Biomedica Earnings Insights

Looking ahead, revenue is expected to decline by 122% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 6.9%.

Performance of the American Pharmaceuticals industry.

The company's shares are up 14% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 4 warning signs for Angion Biomedica you should be aware of, and 2 of them are a bit concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.